Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Viatris Inc. (VTRS) Guidance & Earnings Results

On 2026-08-06 Viatris Inc. raised guidance: "Raised midpoints for all 2026 financial…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VTRSViatris Inc.Follow VTRS — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
20.7B
P/E TTM
—
Dividend yield
2.7%
52-week
—
Next earnings
5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26RaisedRaised midpoints for all 2026 financial metrics · full year
7 May 26ReaffirmedReaffirmed 2026 financial guidance; expects >$2.5B cash available for deployment · full year
26 Feb 26Reaffirmed2026 financial guidance provided; positioned for sustainable growth · full year
6 Nov 25RaisedRaised and narrowed 2025 guidance for total revenues, adjusted EBITDA and adjusted EPS · full year
7 Aug 25ReaffirmedFY2025 Total Revenues $13.5-14.0B (midpoint $13.75B); Adjusted EBITDA $3.89-4.19B (midpoint $4.04B); Adjusted EPS $2.16-2.30 (midpoint $2.23); Free Cash Flow $1.8-2.2B (midpoint $2.0B); U.S. GAAP net cash from operations $2.2-2.5B (midpoint $2.35B) · full year

Viatris Inc. — questions

What guidance did Viatris Inc. give?
On 2026-08-06: "Raised midpoints for all 2026 financial metrics"
When does Viatris Inc. report earnings?
Viatris Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Viatris Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.